Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. - Wikidata - awgldk - TriplyDB

Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer.

Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer.

http://www.wikidata.org/entity/Q34644719

about

Combination chemotherapy versus single-agent chemotherapy during preoperative chemoradiation for resectable rectal cancer Radiotherapy for Colorectal Cancer: Current Standards and Future Perspectives Management of colorectal cancer Current treatment of rectal cancer adapted to the individual patient Neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer Review of systemic therapies for locally advanced and metastatic rectal cancer Systematic review and meta-analysis of preoperative chemoradiotherapy with or without oxaliplatin in locally advanced rectal cancer.Radiation Therapy Intensification for Solid Tumors: A Systematic Review of Randomized Trials A multicenter phase I study of preoperative chemoradiotherapy with S-1 and irinotecan for locally advanced lower rectal cancer (SAMRAI-1)Neoadjuvant therapy before surgical treatment Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04 Efficacy and short-term outcomes of preoperative chemoradiotherapy with intermittent oral tegafur-uracil plus leucovorin in Japanese rectal cancer patients: a single center experience retrospective analysis.Meta-analysis of oxaliplatin-based versus fluorouracil-based neoadjuvant chemoradiotherapy and adjuvant chemotherapy for locally advanced rectal cancer.Abdominoperineal excision following preoperative radiotherapy for rectal cancer: unfavorable prognosis even with negative circumferential resection margin Overview of radiation therapy for treating rectal cancer.Oxaliplatin-based adjuvant chemotherapy without radiotherapy can improve the survival of locally-advanced rectal cancer Management of oligometastatic rectal cancer: is liver first?A phase I dose escalation study of oxaliplatin plus oral S-1 and pelvic radiation in patients with locally advanced rectal cancer (SHOGUN trial).Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer.Early increase in circulating carbonic anhydrase IX during neoadjuvant treatment predicts favourable outcome in locally advanced rectal cancer.A novel strategy of radiofrequency hyperthermia (neothermia) in combination with preoperative chemoradiotherapy for the treatment of advanced rectal cancer: a pilot study.Chemotherapy Alone for Patients With Stage II/III Rectal Cancer Undergoing Radical Surgery Fluorouracil-based neoadjuvant chemoradiotherapy with or without oxaliplatin for treatment of locally advanced rectal cancer: An updated systematic review and meta-analysis Clinical parameters predicting pathologic complete response following neoadjuvant chemoradiotherapy for rectal cancer.2011 update in gastrointestinal cancer therapeutics Personalized radiotherapy: concepts, biomarkers and trial design Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer Pathologic complete response and disease-free survival are not surrogate endpoints for 5-year survival in rectal cancer: an analysis of 22 randomized trials.Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer.Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.Fluorouracil-based preoperative chemoradiotherapy with or without oxaliplatin for stage II/III rectal cancer: a 3-year follow-up study The best timing for administering systemic chemotherapy in patients with locally advanced rectal cancer A prospective feasibility study to evaluate neoadjuvant-synchronous S-1 with radiotherapy for locally advanced rectal cancer: A multicentre phase II trial.Outcomes of neoadjuvant chemoradiotherapy in Japanese locally advanced rectal carcinoma patients.The status of targeted agents in the setting of neoadjuvant radiation therapy in locally advanced rectal cancers.Selecting patients with locally advanced rectal cancer for neoadjuvant treatment strategies.An observational study of extending FOLFOX chemotherapy, lengthening the interval between radiotherapy and surgery, and enhancing pathological complete response rates in rectal cancer patients following preoperative chemoradiotherapy.Comparison between preoperative and postoperative concurrent chemoradiotherapy for rectal cancer: an institutional analysis Interim analysis of postoperative chemoradiotherapy with capecitabine and oxaliplatin versus capecitabine alone for pathological stage II and III rectal cancer: a randomized multicenter phase III trial.Neo-adjuvant radiotherapy in rectal cancer.

P2860

Q24186443-55EDBB9C-590F-4220-8557-6CF3214F50AF Q26738806-C72D1E5D-DAD0-4030-AB23-84377F0FFCD9 Q26823550-90E9C98E-34C1-4AA3-94E4-B29637054D13 Q26824553-1F10A9CC-F183-4669-9A46-7612DDC21CF5 Q27003878-7D20D76A-CDD3-4628-8D3E-B08A63802528 Q27021105-85BC5CEA-E515-42B7-8C44-09D45D8BB440 Q30235044-89BF6D94-E64F-4368-AD89-749B8C1720EE Q30278410-9F3A6F46-4835-4D54-8749-47DA91A93F4D Q33433227-001FB78D-A6C0-4B29-8352-4B0D79A43C6A Q33697924-78457CB0-DBA2-4F0B-8495-C1A1A56667A3 Q33729092-F8848FF5-FCD6-4D6A-B135-AB7A119CDDF1 Q33749847-2023D8B9-5127-4D92-9D94-40C5B13557A9 Q33798353-0854812B-2F76-4DC0-8703-38AC311DF5B7 Q33958747-2D1B3305-1411-4035-BC22-44FD37CA3594 Q34136267-45B96DA9-59A6-40A0-A2B4-11FBA1017874 Q34226859-6D8588FA-A71F-4618-ABEE-74FC67753B61 Q35029056-A522820E-E631-4581-B1CA-5A9D40B0890A Q35033392-1E65FB78-5F87-41EC-89BC-C773CE350F7E Q35269337-B6C680D2-BB41-4D78-9F08-EA50F7FD6852 Q35709494-265C1491-0985-40B9-91FD-EFFCEEB54982 Q35755378-FF1B6235-9916-4FD6-977D-0D69013D23BB Q35820586-898DDAEC-1247-4841-B7DD-B8BE313FD758 Q36056754-57672A4B-58A8-4265-AC29-4382C0E2C508 Q36121224-0E1BDB62-1DA6-47DC-BE72-61841CBA6E2F Q36211003-02C72ACD-A7B5-4A1A-9482-5CD9E627DEBC Q36235704-891BC49B-C425-43A6-ACCE-1DB16A68CA39 Q36300533-36739629-4026-439A-A79A-4CAAA3331D71 Q36303649-BB45B098-B091-4C0C-9383-74E9B340BAB9 Q36324953-5CB1B578-CB7D-4809-AB9F-79C064FC602A Q36348179-157BC062-72BC-4226-9F3D-20FB8A6F7137 Q36419121-6697EBA0-B826-45ED-AB8B-815B576EC782 Q36516445-F72DE646-8D44-4B85-9629-0C9AFDCC51F9 Q36742214-03557295-C735-4DA1-B7DC-D90670671249 Q36853674-1415AEE7-C8FA-430E-9409-0690B53F9E9F Q37015715-19E5FB5B-9F3B-499F-89FC-3684DA28FB61 Q37038486-3055C68E-D491-4419-94AF-6A8EC3F26D2A Q37173767-AD1683C6-1407-4124-9ECC-F9E0B7419424 Q37231196-8BD9702A-CEF6-4851-AC71-F35657BCEA4F Q37295422-49C8C824-08BE-4291-A281-3A667A2A89A3 Q37408813-E1AE8704-7497-4EF7-B76C-8C1B75C71140

P2860

Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer.

http://www.wikidata.org/entity/Q34644719

description

2012 nî lūn-bûn

@nan

2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer.

@ast

Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer.

@en

Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer.

@nl

type

label

Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer.

@ast

Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer.

@en

Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer.

@nl

prefLabel

Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer.

@ast

Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer.

@en

Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer.

@nl

P1433

Q34644719-6CFA9889-BB13-4BA6-A492-1E8BCF2A0617

P1476

Q34644719-0F59F04F-ACC5-4EFD-B538-590AC5A7E2BF

P2093

Q34644719-2122AEB1-34F5-4F08-9562-D20B3CD6DAB7

Q34644719-2214AC34-10D1-44A2-9065-1CE9659B4952

Q34644719-2A58073B-172C-40AD-96A0-F724BD644E89

Q34644719-2E5D424E-0E2C-41B2-93AF-BF13B8311882

Q34644719-33C4311F-BFA0-4546-9CD7-C0193E52719B

Q34644719-4E4C235B-E0AA-45EF-A505-A1825A8A7D25

Q34644719-5438B23D-02E3-4CB2-87E7-D4D33D54CF1A

Q34644719-56EBCF46-6085-48AF-AE73-C7E174B14AD1

Q34644719-5D091DE5-0F59-437E-8C25-9C4C11D0B631

Q34644719-5D9434FF-D489-488F-8DFB-CB885925FC00

P304

Q34644719-3D57863F-31AE-4DCC-8C78-2DACDF80405F

P31

Q34644719-0D84A698-D801-4901-8D7E-328F0CB01BB4

P356

Q34644719-58C221BF-D36B-4A5B-BB70-FD7A768E7435

P407

Q34644719-A3AC94B9-DD15-4993-B089-3B9157BEBE93

P433

Q34644719-AA7928E7-2727-46BB-A711-9226BC567E05

P478

Q34644719-3E2EE839-4AFF-4C8A-85EC-4B2BA026B9C8

P577

Q34644719-05B4035D-A83D-437C-966A-486D2AC70729

P698

Q34644719-16F7C4CB-38DD-4D9C-A4F2-A5341EA48C7E

P356

JCO.2012.42.8771

P1433

Journal of Clinical Oncology

P1476

Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer.

@en

P2093

Bernard Denis

http://www.w3.org/2001/XMLSchema#string

Béata Juzyna

http://www.w3.org/2001/XMLSchema#string

Christophe Hennequin

http://www.w3.org/2001/XMLSchema#string

David Azria

http://www.w3.org/2001/XMLSchema#string

Eric François

http://www.w3.org/2001/XMLSchema#string

Guy de La Roche

http://www.w3.org/2001/XMLSchema#string

Gérard Lledo

http://www.w3.org/2001/XMLSchema#string

Isabelle Martel-Lafay

http://www.w3.org/2001/XMLSchema#string

Jean-François Berdah

http://www.w3.org/2001/XMLSchema#string

Jean-François Seitz

http://www.w3.org/2001/XMLSchema#string

P304

4558-4565

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2012.42.8771

http://www.w3.org/2001/XMLSchema#string

P407

P433

36

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P577

2012-10-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23109696

http://www.w3.org/2001/XMLSchema#string